Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.